page header

Contents  ·  Introduction  ·  Learning  Objectives  ·  Textbook  ·  Lectures  ·  Procedures  ·  Final Exam  ·  Library  ·  Laboratory  ·  Pharmacy  ·  Imaging  ·  Forms  ·  Videos  ·  About  ·  Contact Us>

Tubocurarine chloride U.S.P.

Category:

  • Muscle relaxant

  Description:

  • Curare class, nondepolarizing skeletal muscle relaxant

  Indications:

  • Adjunct to general anesthesia to facilitate intubation and skeletal muscle relaxation

  • Diagnostic agent for myasthenia gravis

  Contraindications:

  • Patients in whom histamine release if a definite hazard.

  Precautions:

  • Pregnancy category C

  • Only used by skilled personnel in airway management and respiratory support.

  • Must have anticholinesterase reversal agents immediately available during use.

  • Will cause histamine release.  Use with caution in patients susceptible to histamine, such as cardiovascular disease and asthma.

  • May cause bradycardia during anesthesia.

  • Use with caution in patients with neuromuscular disease.

  • Use in caution in elderly due to increased dosage requirements and recovery times.

  • Does not alter consciousness or relieve pain.

  • Use a peripheral nerve stimulator to monitor twitch suppression and recovery.

  • IM injection may cause tissue irritation.

Adverse Reactions (Side Effects):

  • Cardiovascular: arrhythmias, cardiac arrest, bradycardia, hypotension

  • Excessive salivation

  • Prolonged respiratory suppression

Dosage:

  • Administered IV as a sustained injection over 1-1.5 minutes or IM

  • Individualize dosage calcualted at 0.1-0.2mg/kg

  • General dosing reference:

    • Adult (70kg): 40-60 units IV at time of incision, 20-30 units in 3-5 minutes if required

    • long operations: supplemental doses of 20 units as required (based on 1.1 units/kg)

    • Electroshock therapy (EST): 1.1 units/kg

    • Myasthenia gravis diagnosis:

    • administer 1/15 to 1/5 of EST dose

    • exaggerated response will occur

    • reverse effect with neostigmine

  • Children: 0.6mg/kg

  • Neonates: 0.3mg/kg

 

 


The information contained here is an abbreviated summary. For more detailed and complete information, consult the manufacturer's product information sheets or standard textbooks

Source: Operational Medicine 2001,  Health Care in Military Settings, NAVMED P-5139, May 1, 2001, Bureau of Medicine and Surgery, Department of the Navy, 2300 E Street NW, Washington, D.C., 20372-5300

This information is provided by The Brookside Associates.  The Brookside Associates, LLC. is a private organization, not affiliated with any governmental agency. The opinions presented here are those of the author and do not necessarily represent the opinions of the Brookside Associates or the Department of Defense. The presence of any advertising on these pages does not constitute an endorsement of that product or service by either the US Department of Defense or the Brookside Associates. All material presented here is unclassified.

C. 2009, 2014, All Rights Reserved

brookside associates logo

 

 

 

 

 

 

Advertise on this site